AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

Key Highlights

• Funding Amount: $73M Series B
• Valuation: Undisclosed
• Headquarters: South Korea
• Founded: 2018
• Employees: 50-100
• Total Raised: $90M

About the Funding Round

AusperBio has successfully closed $73M Series B in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

• HanKang Capital

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help AusperBio achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. AusperBio's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2018 and headquartered in South Korea, AusperBio has established itself as an innovative player in the biotech space. With 50-100 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, AusperBio plans to:

• Accelerate product development and innovation
• Expand into new markets and geographies
• Grow the team across engineering, sales, and operations
• Strengthen partnerships with key industry players
• Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in AusperBio's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about AusperBio, visit their website or contact their press office.